Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients

S G P Funnell; W E Dowling; C Muñoz-Fontela; P-S Gsell; D E Ingber; G A Hamilton; L Delang; J Rocha-Pereira; S Kaptein; K H Dallmeier; J Neyts; K Rosenke; E de Wit; H Feldmann; P Maisonnasse; R Le Grand; M B Frieman; C M Coleman

doi:10.1038/s41467-020-17907-w

Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients

Nat Commun. 2020 Aug 26;11(1):4253. doi: 10.1038/s41467-020-17907-w.

Authors

S G P Funnell¹, W E Dowling², C Muñoz-Fontela³, P-S Gsell⁴, D E Ingber⁵, G A Hamilton⁶, L Delang⁷, J Rocha-Pereira⁷, S Kaptein⁷, K H Dallmeier⁷, J Neyts⁷, K Rosenke⁸, E de Wit⁸, H Feldmann⁸, P Maisonnasse⁹, R Le Grand⁹, M B Frieman¹⁰, C M Coleman¹¹

Affiliations

¹ National Infection Service, Public Health England, Porton Down, Manor Farm Road, Salisbury, Wiltshire, SP40JG, UK. [email protected].
² Coalition for Epidemic Preparedness Innovations, 1901 Pennsylvania Avenue, NW, Suite 1003, Washington, DC, 20006, USA.
³ Bernhard Nocht Institute for Tropical Medicine, Bernhard Nocht Strasse. 74, 20359, Hamburg, Germany.
⁴ World Health Organisation, Avenue Appia, 1211, Geneva, Switzerland.
⁵ Wyss Institute for Biologically Inspired Engineering, Harvard University, CLSB5, 3 Blackfan Circle, Boston, MA, 02115, USA.
⁶ Emulate Inc., 27 Drydock Avenue, 5th Floor, Boston, MA, 02210, USA.
⁷ Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute, Global Virus Network, KU Leuven, 3000, Leuven, Belgium.
⁸ Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institute of Health, Hamilton, 59840, MT, USA.
⁹ Université Paris-Saclay, Inserm, CEA, Center for Immunology of Viral, Auto-immune, Hematological and Bacterial diseases » (IMVA-HB/IDMIT), Fontenay-aux-Roses & Le Kremlin-Bicêtre, 92265, France.
¹⁰ Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
¹¹ School of Life Sciences, University of Nottingham, Queen's Medical Centre, Nottingham, NG7 2UH, UK.

Abstract

There is an urgent need for drugs, therapies and vaccines to be available to protect the human population against COVID-19. One of the first approaches taken in the COVID-19 global response was to consider repurposing licensed drugs. This commentary highlights an extraordinary international collaborative effort of independent researchers who have recently all come to the same conclusion—that chloroquine or hydroxchloroquine are unlikely to provide clinical benefit against COVID-19.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

MeSH terms

Animals
Antiviral Agents / therapeutic use*
Betacoronavirus* / drug effects
Betacoronavirus* / pathogenicity
COVID-19
COVID-19 Drug Treatment
Coronavirus Infections / drug therapy*
Cricetinae
Humans
Hydroxychloroquine / therapeutic use*
Mice
Models, Biological*
Pandemics
Pneumonia, Viral / drug therapy*
Primates
SARS-CoV-2
Treatment Failure

Substances

Antiviral Agents
Hydroxychloroquine

Abstract

Publication types

MeSH terms

Substances

Grants and funding